CPRX News and Press, Catalyst Pharmaceuticals Inc. From 07/17/19

Editor's note: Seeking Alpha is proud to welcome Illuminate Capital as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Editor's not...

Key investment thesis: Catalyst Pharmaceuticals ( CPRX ) stock is cut in more than half after FDA approved rival Jacobus’s therapy Ruzurgi (3,4-DAP) in treating pediatric Lambert-Eaton myasthenic syndrome, LEMS. Investors feared two things: (1) Prescribing clinicians may prefer to p...

Citing violations of its own regulations, Catalyst Pharmaceuticals (NASDAQ: CPRX ) is suing the FDA over its recent approval (May 6) of Jacobus Pharmaceutical Company's Ruzurgi (amifampridine) for the treatment of children with an autoimmune disorder called Lambert-Eaton syndrome  (LEM...

CORAL GABLES, Fla., June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration (FDA) and several related parties challenging the recent approval of a new drug application and re...

CORAL GABLES, Fla., June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) has amended its license agreement for Firdapse to expand its commercial territory. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

CORAL GABLES, Fla., May 30, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today ...

Catalyst Pharmaceuticals (NASDAQ: CPRX ) discloses that it has settled a patent dispute with Northwestern University related to pipeline candidate CPP-115. More news on: Catalyst Pharmaceuticals, Inc., Healthcare stocks news, Read more ...

For the past several months, Florida-based Catalyst Pharmaceuticals (NASDAQ: CPRX ) has taken its investors on a bumpy ride. After Catalyst received approval for its lead drug candidate Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in November 2018, the stock pric...

Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...